Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w